Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 20/20 | 1.00 |
| ▸ | CCR3 | P51677 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372671 | 1.00 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| Water SCHEMBL5664137 | 0.99 | HRH1 (0.98) | HRH1CCR3KCNH2 | |
| SCHEMBL5409212 | 0.94 | HRH1 (0.88) | HRH1CCR3KCNH2 | |
| SCHEMBL5403880 | 0.93 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5422912 | 0.93 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5426618 | 0.92 | HRH1 (0.88) | HRH1CCR3KCNH2 | |
| SCHEMBL5409440 | 0.91 | HRH1 (0.86) | HRH1CCR3KCNH2 | |
| SCHEMBL5419482 | 0.91 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5409233 | 0.91 | HRH1 (1.00) | HRH1CCR3KCNH2 | |
| SCHEMBL5403941 | 0.90 | HRH1 (0.82) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | claimed |
| US-20070276141-A1 | Preparation of Pharmaceutical Salts of [1,4] - Bipiperidine | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | claimed |
| EP-1682139-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF 1, 4 - BIPIPERIDINE | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | claimed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | claimed |
| WO-2005044268-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF [1, 4] - BIPIPERIDINE | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | claimed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | claimed |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2022-05-05 | — | — | US | disclosed |
| US-11253540-B2 | Composition including glycosaminoglycan derivative and chemokine receptor activity regulator | SEIKAGAKU CORPORATION (JP) | 2022-02-22 | — | — | US | disclosed |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | UNIVERSITE PAUL SABATIER (TOULOUSE III) (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20180140628-A1 | COMPOSITION INCLUDING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | SEIKAGAKU CORPORATION (JP) | 2018-05-24 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-05-11 | — | — | US | disclosed |
| US-7307090-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-12-11 | — | — | US | disclosed |
| EP-1404667-B1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-03-08 | — | — | EP | disclosed |
| EP-1604982-A1 | INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005044268-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF [1, 4] - BIPIPERIDINE | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044268-A1 | PREPARATION OF PHARMACEUTICAL SALTS OF [1, 4] - BIPIPERIDINE | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-11-25 | — | — | US | disclosed |
| EP-1404667-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003004487-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235894-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR1, CCR3, CCRL2 | HRH1 25/4885CCR3 2/4885KCNH2 1672/4885 |
| US-20170131282-A1 | Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer | CCR3, CCR5, CCR1 | HRH1 1795/4885CCR3 1/4885KCNH2 4859/4885 |
| US-10401365-B2 | Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer | CCR3, CCR5, CCR1 | HRH1 1870/4885CCR3 1/4885KCNH2 4861/4885 |
| US-11253540-B2 | Composition including glycosaminoglycan derivative and chemokine receptor activity regulator | CCL5, CCL2, ACKR3 | HRH1 1979/4885CCR3 12/4885KCNH2 4852/4885 |
| US-20180140628-A1 | COMPOSITION INCLUDING GLYCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, ACKR3 | HRH1 1979/4885CCR3 12/4885KCNH2 4852/4885 |
| US-20070276141-A1 | Preparation of Pharmaceutical Salts of [1,4] - Bipiperidine | CCR3, CCR1, CCR4 | HRH1 55/4885CCR3 1/4885KCNH2 986/4885 |
| US-20220133776-A1 | COMPOSITION INCLUDING GLUCOSAMINOGLYCAN DERIVATIVE AND CHEMOKINE RECEPTOR ACTIVITY REGULATOR | CCL5, CCL2, ACKR3 | HRH1 3261/4885CCR3 16/4885KCNH2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.